- Home
- CYH vs OMER Comparison
CYH vs OMER Comparison
Compare CYH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- OMER
- Stock Information
- Founded
- CYH 1985
- OMER 1994
- Country
- CYH United States
- OMER United States
- Employees
- CYH N/A
- OMER N/A
- Industry
- CYH Hospital/Nursing Management
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- OMER Health Care
- Exchange
- CYH Nasdaq
- OMER Nasdaq
- Market Cap
- CYH 348.9M
- OMER 304.9M
- IPO Year
- CYH 1991
- OMER 2009
- Fundamental
- Price
- CYH $2.85
- OMER $4.13
- Analyst Decision
- CYH Hold
- OMER Strong Buy
- Analyst Count
- CYH 8
- OMER 5
- Target Price
- CYH $3.57
- OMER $18.00
- AVG Volume (30 Days)
- CYH 1.7M
- OMER 996.4K
- Earning Date
- CYH 10-22-2025
- OMER 08-14-2025
- Dividend Yield
- CYH N/A
- OMER N/A
- EPS Growth
- CYH N/A
- OMER N/A
- EPS
- CYH N/A
- OMER N/A
- Revenue
- CYH $12,647,000,000.00
- OMER N/A
- Revenue This Year
- CYH N/A
- OMER N/A
- Revenue Next Year
- CYH $2.46
- OMER $9,040.39
- P/E Ratio
- CYH N/A
- OMER N/A
- Revenue Growth
- CYH 0.81
- OMER N/A
- 52 Week Low
- CYH $2.24
- OMER $2.95
- 52 Week High
- CYH $6.29
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CYH 49.03
- OMER 50.30
- Support Level
- CYH $2.69
- OMER $4.08
- Resistance Level
- CYH $2.86
- OMER $4.43
- Average True Range (ATR)
- CYH 0.10
- OMER 0.26
- MACD
- CYH 0.04
- OMER -0.04
- Stochastic Oscillator
- CYH 63.79
- OMER 16.67
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.